- Home
- DRTS vs VNDA Comparison
DRTS vs VNDA Comparison
Compare DRTS & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRTS
- VNDA
- Stock Information
- Founded
- DRTS 2015
- VNDA 2002
- Country
- DRTS Israel
- VNDA United States
- Employees
- DRTS N/A
- VNDA N/A
- Industry
- DRTS Medical/Dental Instruments
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- DRTS Health Care
- VNDA Health Care
- Exchange
- DRTS Nasdaq
- VNDA Nasdaq
- Market Cap
- DRTS 300.2M
- VNDA 249.4M
- IPO Year
- DRTS N/A
- VNDA 2006
- Fundamental
- Price
- DRTS $3.65
- VNDA $4.58
- Analyst Decision
- DRTS Strong Buy
- VNDA Strong Buy
- Analyst Count
- DRTS 1
- VNDA 2
- Target Price
- DRTS $9.00
- VNDA $16.50
- AVG Volume (30 Days)
- DRTS 67.0K
- VNDA 460.3K
- Earning Date
- DRTS 08-11-2025
- VNDA 11-05-2025
- Dividend Yield
- DRTS N/A
- VNDA N/A
- EPS Growth
- DRTS N/A
- VNDA N/A
- EPS
- DRTS N/A
- VNDA N/A
- Revenue
- DRTS N/A
- VNDA $203,467,000.00
- Revenue This Year
- DRTS N/A
- VNDA $15.45
- Revenue Next Year
- DRTS N/A
- VNDA $37.82
- P/E Ratio
- DRTS N/A
- VNDA N/A
- Revenue Growth
- DRTS N/A
- VNDA 11.78
- 52 Week Low
- DRTS $2.11
- VNDA $3.81
- 52 Week High
- DRTS $4.39
- VNDA $5.55
- Technical
- Relative Strength Index (RSI)
- DRTS 66.81
- VNDA 49.77
- Support Level
- DRTS $3.35
- VNDA $4.54
- Resistance Level
- DRTS $3.63
- VNDA $4.92
- Average True Range (ATR)
- DRTS 0.15
- VNDA 0.16
- MACD
- DRTS 0.03
- VNDA 0.01
- Stochastic Oscillator
- DRTS 101.56
- VNDA 24.38
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.